Evidence map›Paper›PMID 33709222›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020).

R Mesia, L Iglesias, J Lambea, J Martínez-Trufero, A Soria, M Taberna, J Trigo, M Chaves, A García-Castaño, J J Cruz-Hernández

Abstract readPublished Erratum
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

R MesiaInstitut Català d'Oncologia, Badalona, Spain. rmesia@iconcologia.net.ORCID http://orcid.org/0000-0002-3785-3563
L IglesiasServicio de Oncología Médica, Hospital Universitario 12 de Octubre, 12 de Octubre, Madrid, Spain.
J LambeaServicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
J Martínez-TruferoServicio de Oncología Médica, Hospital Universitario Miguel Servet, Zaragoza, Spain.
A SoriaServicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain.
M TabernaInstitut Català d'Oncologia, Hospitalet de Llobregat, Spain.
J TrigoServicio de Oncología Médica, Hospital Clínico Virgen de la Victoria, Málaga, Spain.
M ChavesServicio de Oncología Médica, Hospital Virgen de Valme, Seville, Spain.
A García-CastañoServicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
J J Cruz-HernándezServicio de Oncología Médica, Hospital Clínico Universitario de Salamanca, Salamanca, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33709222
PMCPMC8182865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.